Related Experiment Video
Updated: Jan 20, 2026

Use of MRI-ultrasound Fusion to Achieve Targeted Prostate Biopsy
Published on: April 9, 2019
68Ga-PSMA-PET/CT and Diffusion MRI Targeting for Cone-Beam CT-Guided Bone Biopsies of Castration-Resistant Prostate
T R F van Steenbergen1, M Smits2, T W J Scheenen3
1Department of Radiology and Nuclear Medicine, Radboud Institute for Health Sciences, Radboud University Medical Center, P.O. Box 9101, 6500 HB, Nijmegen, The Netherlands. Thomas.vansteenbergen@radboudumc.nl.
Introduction:
Precision medicine expands the treatment options for metastatic castration-resistant prostate cancer (mCRPC) by targeting druggable genetic aberrations. Aberrations can be identified following molecular analysis of metastatic tissue. Bone metastases, commonly present in mCRPC, hinder precision medicine due to a high proportion of biopsies with insufficient tumor cells for next-generation DNA sequencing. We aimed to investigate the feasibility of incorporating advanced target planning and needle guidance in bone biopsies and whether this procedure increases biopsy tumor yield and success rate of molecular analysis as compared to the current standards, utilizing only CT guidance.
Materials And Methods:
In a pilot study, ten mCRPC patients received 68Ga-prostate-specific membrane antigen (PSMA)-PET/CT and diffusion-weighted MRI as biopsy planning images. These datasets were fused for targeting metastatic lesions with high tumor densities. Biopsies were performed under cone-beam CT (CBCT) guidance. Feasibility of target planning and needle guidance was assessed, and success of molecular analysis and tumor yield were reported.
Results:
Fusion target planning and CBCT needle guidance were feasible. Nine out of ten biopsies contained prostate cancer cells, with a median of 39% and 40% tumor cells by two different sequencing techniques. Molecular analysis was successful in eight of ten patients (80%). This exceeds previous reports on CT-guided biopsies that ranged from 33 to 44%. In two patients, important druggable aberrations were found.
Discussion:
A biopsy procedure using advanced target planning and needle guidance is feasible and can increase the success rate of molecular analysis in bone metastases, thereby having the potential of improving treatment outcome for patients with mCRPC.
Level Of Evidence:
Level 4, case series.
Insights
Advanced biopsy techniques improve molecular analysis success in metastatic prostate cancer bone lesions. This approach enhances tumor cell yield, potentially improving treatment outcomes for patients with mCRPC.
Area of Science:
- Oncology
- Radiology
- Molecular Diagnostics
Background:
- Metastatic castration-resistant prostate cancer (mCRPC) treatment relies on precision medicine targeting genetic aberrations.
- Bone metastases in mCRPC often yield insufficient tumor cells for molecular analysis via standard biopsies.
- Current CT-guided bone biopsies have limited success rates for molecular profiling.
Purpose of the Study:
- To assess the feasibility of advanced target planning and needle guidance for bone biopsies in mCRPC.
- To determine if this enhanced biopsy method increases tumor cell yield and molecular analysis success.
- To compare the outcomes with standard CT-guided biopsy techniques.
Main Methods:
- A pilot study involved ten mCRPC patients undergoing 68Ga-PSMA-PET/CT and diffusion-weighted MRI for biopsy planning.
- Image fusion was used to target metastatic lesions with high tumor density.
- Biopsies were performed using cone-beam CT (CBCT) guidance for precise needle placement.
Main Results:
- The advanced target planning and CBCT needle guidance were feasible.
- Nine out of ten biopsies (90%) contained prostate cancer cells, with median tumor cell percentages of 39% and 40%.
- Molecular analysis success rate was 80% (8/10 patients), significantly higher than reported rates for CT-guided biopsies (33-44%).
- Druggable genetic aberrations were identified in two patients.
Conclusions:
- Advanced biopsy techniques integrating imaging fusion and CBCT guidance are feasible for mCRPC bone metastases.
- This method significantly increases the success rate of molecular analysis compared to conventional approaches.
- The improved molecular profiling has the potential to enhance treatment selection and outcomes for mCRPC patients.
More Related Videos
Related Concept Videos
Imaging Studies I: CT and MRI
Description of the Procedures
Computed Tomography (CT) scan:
Computed Tomography (CT) scans use X-ray technology to generate detailed images of bones, organs, and tissues. During the scan, the patient lies on a moving table...
Radiological Investigation I: X-ray and CT
Imaging Studies for Cardiovascular System V: CT
Imaging Studies for Cardiovascular System VI: Calcium -Scoring CT
Treatment Resistant Cancers
Targeted Cancer Therapies
There are several types of targeted therapies against...

